araag2/HINT huggingface dataset:
Clinical trial NCT00193726 (phase 3, status: terminated)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: tab premarin (ethinyl estradiol), placebo
SMILES: [H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    the accrual was very slow and there were many competing studies ongoing/initiated .
  
Eligibility criteria:

        Inclusion Criteria:

          -  1. Patients with histological or cytologic proof of breast cancer. 2. Patients with
             operable breast cancer. 3. Patients who are candidates for adjuvant chemotherapy
             according to the standard policy. 4. Patients who have no contraindication to
             anthracycline based chemotherapy. 5. Patients who give informed consent to participate
             in the study. 6. Patients who can be followed up and can take all cycles of
             chemotherapy at the participating institution. 7. Patients should not have a known
             second cancer, present or past.

        Exclusion Criteria:

        -
Clinical trial NCT01680341 (phase 3, status: completed)
Conditions: diabetes, diabetes mellitus, type 2
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65, E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: insulin degludec/insulin aspart, insulin degludec/insulin aspart
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Type 2 diabetes (diagnosed clinically) for at least 24 weeks prior to Visit 2
             (randomisation)

          -  Currently treated with IGlar (Insulin Glargine) and up to 3 oral antidiabetic drugs
             (OADs) (metformin, DPP-4 inhibitor, sulphonylurea/glinide or alpha-glucosidase
             inhibitor). All antidiabetic treatments should have been ongoing for at least 12 weeks
             prior to Visit 2 (randomisation) and doses should have been stable in this period of
             time

          -  Glycosylated haemoglobin (HbA1c) 7.0-10.0% (both inclusive) by central laboratory
             analysis

          -  Body mass index (BMI) below or equal to 40 kg/m^2

        Exclusion Criteria:

          -  Treatment with glucagon-like peptide 1 (GLP-1) receptor agonists or thiazolidinediones
             (TZDs) both within the last 12 weeks prior to Visit 2 (randomisation)

          -  Stroke; heart failure New York Heart Association (NYHA) class III or IV; myocardial
             infarction; unstable angina pectoris; or coronary arterial bypass graft or
             angioplasty; all within the last 24 weeks prior to Visit 2 (randomisation)

          -  Uncontrolled or untreated severe hypertension defined as systolic blood pressure above
             or equal to 180 mmHg and/or diastolic blood pressure above or equal to 100 mmHg

          -  Recurrent severe hypoglycaemia (more than 1 severe hypoglycaemic event during last 12
             months) or hypoglycaemic unawareness as judged by the investigator

          -  Life-threatening disease (e.g. cancer)
Clinical trial NCT00383877 (phase 3, status: completed)
Conditions: diabetes, diabetes mellitus, type 2
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65, E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: insulin detemir, insulin nph
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Type 2 diabetes

          -  HbA1C greater than 7.5% and less than or equal to 11.0%

          -  Currently on any oral antidiabetic drug (OAD) more than or equal to 3 months

        Exclusion Criteria:

          -  Previous acute treatment with insulin for more than 7 days.

          -  Treatment with OAD(s) which does not adhere to the approval labeling.

          -  Proliferate retinopathy or maculopathy that has required acute treatment within the
             last year.

          -  Known hypoglycaemia unawareness or recurrent major hypoglycaemia, that may interfere
             with study participation as judged by the Investigator.
Clinical trial NCT00402428 (phase 3, status: completed)
Conditions: chronic hepatitis c
ICD codes: B18.2, B18.0, B18.1, B18.8, B18.9, K71.3, K71.4
Drugs: albumin interferon alfa-2b, peginterferon alfa-2a, ribavirin
SMILES: CC1=CC(O)=CC(C)=C1Cl, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Eligibility criteria:

        Key Inclusion Criteria:

          -  Diagnosis of chronic hepatitis C.

          -  Liver biopsy performed within 2 years of Day 0 or during screening.

          -  Infected with hepatitis C virus genotype 1.

          -  Interferon alfa treatment naïve (ie, have never been treated with an interferon
             product).

          -  Subjects are eligible to enter the study if they (or their partners) are not pregnant
             or nursing, are sterile, or of non childbearing potential, or are willing to practice
             abstinence or use appropriate birth control methods during the study and for 7 months
             after the last dose of ribavirin.

          -  Have compensated liver disease.

        Key Exclusion Criteria:

          -  Decompensated liver disease including those subjects with a past history or presence
             of ascites, bleeding varices or hepatic encephalopathy.

          -  History of moderate, severe or uncontrolled psychiatric disease, especially
             depression, including a history of hospitalization or prior suicidal attempt.

          -  Positive for human immunodeficiency virus (HIV-1) or hepatitis B surface antigen
             (HBsAG).

          -  Clinical diagnosis of other causes of chronic liver disease including but not limited
             to hepatitis B, autoimmune hepatitis, primary biliary cirrhosis, alcoholic liver
             disease, hemochromatosis, Wilson's Disease, or alpha 1-antitrypsin deficiency.

          -  A history of immunologically mediated disease (eg, rheumatoid arthritis, inflammatory
             bowel disease, moderate/severe psoriasis, sarcoidosis, systemic lupus erythematosus).

          -  Active seizure disorder within the last 2 years.

          -  Organ transplant other than cornea and hair transplant.

          -  Clinically significant hemoglobinopathy (eg, thalassemia, sickle cell anemia).

          -  Cancer within the last 5 years(with the exception of adequately treated basal cell
             carcinoma of the skin or in situ carcinoma of the uterine cervix).

          -  Drug or alcohol addiction within the last 6 months. Subjects in a supervised methadone
             treatment program may be enrolled in the study.

          -  Received any experimental agent within 28 days prior to Day 0.
Clinical trial NCT00423085 (phase 3, status: completed)
Conditions: alzheimer's disease
ICD codes: G30.8, G30.9, G30.0, G30.1
Drugs: rivastigmine transdermal patch, placebo
SMILES: CCN(C)C(=O)OC1=CC=CC(=C1)[C@H](C)N(C)C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  A diagnosis of dementia of the Alzheimer's type according to the DSM-IV criteria

          -  A clinical diagnosis of probable AD according to NINCDS/ADRDA criteria

          -  An MMSE score of > or = 10 and < or = 20

        Exclusion Criteria:

          -  A current DSM-IV diagnosis of major depression

          -  Taken rivastigmine in the past

          -  A score of > 5 on the Modified Hachinski Ischemic Scale (MHIS) Other protocol-defined
             inclusion/exclusion criteria may apply

        Other protocol-defined inclusion/exclusion criteria may apply

        Extension Phase Eligibility Criteria

        Inclusion Criteria:

          -  Patients who have completed the Double-blind Treatment Phase on study medication

        Exclusion Criteria

          -  Patients who have any important protocol deviations until the completion of the
             Double-blind Treatment Phase
Clinical trial NCT01041859 (phase 3, status: completed)
Conditions: diabetic peripheral neuropathy
ICD codes: A18.2, H11.043, H11.053, H18.463, H35.40, H81.393, I73.9
Drugs: tapentadol extended release (er), placebo
SMILES: CC[C@H]([C@@H](C)CN(C)C)C1=CC(O)=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with Type 1 or 2 diabetes mellitus must have a documented clinical diagnosis
             of painful diabetic peripheral neuropathy with symptoms and signs for at least 6
             months, and pain present at the time of screening

          -  Diagnosis must include pain plus reduction or absence of pin sensibility and/or
             vibration sensibility on Total Neuropathy Score - Nurse (TNSn) examination in lower
             and/or upper extremities at screening

          -  The investigator considers the patient's blood glucose to be controlled by diet, or
             hypoglycemics, or insulin for at least 3 months prior to enrolling in the study

          -  Patients have been taking analgesic medications for the condition for at least 3
             months prior to screening (patients taking opioid analgesics must be dissatisfied with
             current treatment, and patients taking non-opioid analgesics must be dissatisfied with
             current analgesia)

          -  Patients currently requiring opioid treatment must be taking daily doses of an
             opioid-based analgesic equivalent to <=160mg of oral morphine

        Exclusion Criteria:

          -  Significant history of pulmonary, gastrointestinal, endocrine, metabolic (except
             diabetes mellitus), neurological, psychiatric disorders (resulting in disorientation,
             memory impairment or inability to report accurately as in schizophrenia)

          -  History of moderate to severe hepatic impairment

          -  Severely impaired renal function

          -  Clinically significant laboratory abnormalities

          -  Clinically significant cardiac disease

          -  History of seizure disorder or epilepsy

          -  History of any other clinically significant disease that in the investigator's opinion
             may affect efficacy or safety assessments or may compromise patient safety during
             study participation
Clinical trial NCT01474109 (phase 3, status: completed)
Conditions: systemic sclerosis, ulcers
ICD codes: M34.0, M34.89, M34.9, M34.82, M34.83, M34.81, M34.2, A66.4
Drugs: macitentan 3mg, macitentan 10mg, placebo
SMILES: CCCNS(=O)(=O)NC1=C(C(OCCOC2=NC=C(Br)C=N2)=NC=N1)C1=CC=C(Br)C=C1, CCCNS(=O)(=O)NC1=C(C(OCCOC2=NC=C(Br)C=N2)=NC=N1)C1=CC=C(Br)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria :

          -  Patients ≥ 18 years of age

          -  Women of childbearing potential must use two reliable methods of contraception

          -  Diagnosis of SSc according to the classification criteria of the American College of
             Rheumatology (ACR)

          -  At least one visible, active ischemic digital ulcers (DU) at baseline

          -  History of at least one additional recent active ischemic DU

        Exclusion Criteria :

          -  DUs due to condition other than SSc

          -  Symptomatic Pulmonary arterial hypertension (PAH)

          -  Body mass index (BMI) < 18 kg/m^2

          -  Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) > 1.5 x upper
             limit of the normal range (ULN)

          -  Hemoglobin < 75% of the lower limit of the normal range

          -  Systolic blood pressure < 95 mmHg or diastolic blood pressure < 50 mmHg

          -  Severe malabsorption; any severe organ failure (e.g., lung, kidney), or any
             life-threatening condition.

          -  Females who are pregnant or breastfeeding or plan to do so during the course of this
             study.

          -  Substance or alcohol abuse or dependence, or tobacco use at any level.

          -  Treatment with phosphodiesterase type-5 (PDE5) inhibitors.

          -  Patients on statins, who have received treatment for less than 3 months prior to
             Screening or whose treatment has not been stable during this period.

          -  Patients on vasodilators, who have received treatment for less than 2 weeks prior to
             Screening or whose treatment has not been stable during this period.

          -  Treatment with prostanoids within 3 months.

          -  Treatment with disease modifying agents if present for less than 3 months prior to
             Screening or whose treatment has not been stable for at least 1 month prior to
             Screening.

          -  Treatment with oral corticosteroids (> 10 mg/day of prednisone or equivalent).

          -  Treatment with ERAs within 3 months.

          -  Systemic antibiotics to treat infected DU(s) within 4 weeks.
Clinical trial NCT00611455 (phase 3, status: terminated)
Conditions: arthritis, rheumatoid
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: ofatumumab, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    ofatumumab iv trials in ra were prematurely terminated because gsk refocused clinical
    development of autoimmune indications on the subcutaneous delivery.
  
Eligibility criteria:

        Inclusion Criteria

          -  Age ≥ 18 years;

          -  Active disease at the time of screening as defined by:

             ≥ 8 swollen joints (of 66 joints assessed) and ≥ 8 tender joints (of 68 joints
             assessed), C-Reactive Protein (CRP) ≥ 1.0 mg/dL or Erythrocyte Sedimentation Rate
             (ESR) ≥ 22 mm/hour, DAS28≥3.2 (based on ESR);

          -  Inadequate response to previous or current methotrexate treatment;

          -  Treatment with methotrexate (MTX), 7.5-25 mg/week, for at least 12 weeks and at a
             stable dose for at least 4 weeks.

        Exclusion Criteria

          -  Patients with a history of a rheumatic autoimmune disease other than RA or with
             significant systemic involvement secondary to RA;

          -  Previous exposure to biologic anti-rheumatic therapies, including investigational
             compounds;

          -  Previous exposure to biologic DMARDs; Chronic or ongoing active infectious disease
             requiring systemic treatment;

          -  Clinically significant cardiac disease; History of significant cerebrovascular
             disease;

          -  Significant concurrent, uncontrolled medical condition including, but not limited to,
             renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, neurological,
             cerebral psychiatric disease, or evidence of demyelinating disease;

          -  Known HIV positive; Serologic evidence of Hepatitis B infection; Positive test for
             Hepatitis C; Positive plasma / white cell JC Virus PCR;

          -  Serum IgG < lower limit of normal;

          -  Breast feeding women or women with a positive pregnancy test at screening;

          -  Current participation in any other interventional clinical study;

          -  Patients known or suspected of not being able to comply with a study protocol.
Clinical trial NCT00998738 (phase 3, status: terminated)
Conditions: neuropathy, pain, recurrent breast carcinoma, stage iv breast cancer
ICD codes: G58.0, G61.1, A52.15, G60.3, G61.82, H46.2, H46.3, N50.82, R07.2, R07.82, R10.13, R10.33, R14.1, R52, C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31, C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: calcium gluconate, magnesium sulfate, ixabepilone
SMILES: [Ca], [MgH2], [H][C@]12C[C@H](NC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC[C@@]1(C)O2)C(\C)=C\C1=CSC(C)=N1
Reason stopped: 
    lack of accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Scheduled to undergo cancer treatment for metastatic breast cancer (weekly or once
             every three weeks) with ixabepilone with no prior exposure to ixabepilone and no more
             than 2 prior chemotherapy regimens for metastatic disease

          -  Serum calcium =< 1.2 x upper normal limit (UNL)

          -  Serum magnesium =< UNL

          -  Serum creatinine =< 1.5 x UNL

          -  Ability to sign informed consent and understand the nature of a placebo-controlled
             trial

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0, 1, or 2

          -  Ability to complete questionnaire(s) by themselves or with assistance

          -  Life expectancy >= 4 months

          -  Presence of a central line

        Exclusion Criteria:

          -  Pre-existing history of peripheral neuropathy >= grade 2 (National Cancer Institute
             [NCI] CTCAE Active Version) due to any cause (chemotherapy, diabetes, alcohol, toxin,
             hereditary, etc.)

          -  Concurrent treatment with anticonvulsants, tricyclic antidepressants, or other
             neuropathic pain medications agents such as carbamazepine, phenytoin, valproic acid,
             gabapentin, lamotrigine, topical lidocaine patch, capsaicin cream, etc., or any other
             treatments specifically for prevention or treatment of neuropathy

          -  Other medical conditions, which in the opinion of the treating physician/allied health
             professional would make this protocol unreasonably hazardous for the patient

          -  Any of the following:

               -  Pregnant women

               -  Nursing women

               -  Women of childbearing potential (per physician judgment)

          -  Diagnosed diabetes requiring insulin or oral hypoglycemic medications

          -  Receiving digoxin or digitoxin

          -  History of heart block (any degree)

          -  Current treatment for arrhythmias

          -  Concurrent treatment with other neuropathic chemotherapy agents
Clinical trial NCT01763866 (phase 3, status: completed)
Conditions: hyperlipidemia
ICD codes: E78.2, E78.49, E78.5
Drugs: ezetimibe, placebo to evolocumab, placebo to ezetimibe, atorvastatin, rosuvastatin, simvastatin
SMILES: CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, O[C@@H](CC[C@@H]1[C@H](N(C1=O)C1=CC=C(F)C=C1)C1=CC=C(O)C=C1)C1=CC=C(F)C=C1, CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1, CC(C)C1=NC(=NC(C2=CC=C(F)C=C2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(=O)O)N(C)S(C)(=O)=O, CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female ≥ 18 to ≤ 80 years of age

          -  Subjects not taking a statin must have fasting LDL-C of at least 150 mg/dL (4.0
             mmol/L)

          -  Subjects already on a non-intensive statin must have fasting LDL-C at screening ≥ 100
             mg/dL (2.6 mmol/L)

          -  Subjects already on a intensive statin must have fasting LDL-C at screening ≥ 80 mg/dL
             (2.1 mmol/L)

          -  Fasting triglycerides ≤ 400 mg/dL (4.5 mmol/L)

        Exclusion Criteria:

          -  Statin intolerance

          -  New York Heart association (NYHA) III or IV heart failure

          -  Uncontrolled hypertension

          -  Uncontrolled cardiac arrhythmia

          -  Type 1 diabetes, poorly controlled type 2 diabetes

          -  Uncontrolled hypothyroidism or hyperthyroidism
Clinical trial NCT01298323 (phase 3, status: active, not recruiting)
Conditions: locally advanced or metastatic medullary thyroid cancer, medullary thyroid cancer
ICD codes: C73, D34, D44.0, Z85.850, C73, D34, D44.0, Z85.850
Drugs: vandetanib
SMILES: [H]\C(=C(\[H])C1=CC=C(OC)C=C1)C(=O)OCC(CC)CCCC
Eligibility criteria:

        Inclusion Criteria:

          -  Provision of informed consent prior to any study specific procedures

          -  Female or male aged 18 years and over

          -  Previously confirmed histological diagnosis of unresectable, locally advanced or
             metastatic hereditary or sporadic MTC. Documentation must be provided in patient's
             medical chart

          -  WHO or ECOG Performance status 0-2

          -  Negative pregnancy test (urine or serum) for female patients of childbearing potential

        Exclusion Criteria:

          -  Unstable brain metastases or spinal cord compression that require treatment, unless
             treated at least 4 weeks before first dose and stable without steroid treatment for 10
             days

          -  Major surgery within 4 weeks before randomization

          -  The last dose of prior chemotherapy received less than 3 weeks prior to randomization

          -  Radiation therapy not completed prior to the first dose of vandetanib

          -  Significant cardiac event, superior vena cava syndrome, NYHA classification of heart
             disease ≥2, within 12 weeks before randomization, or presence of cardiac disease that
             in the opinion of the Investigator increases risk of ventricular arrhythmia

          -  Creatinine clearance <30 ml/min (calculated by Cockcroft-Gault formula),Patients with
             moderate renal impairment, defined as creatinine clearance ≥30 to <50 ml/min, must
             start vandetanib at a reduced dose of 200 mg
Clinical trial NCT01020448 (phase 3, status: completed)
Conditions: prostate cancer
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: triptorelin (decapeptyl®)
SMILES: CC(C)C[C@H](NC(=O)[C@@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O
Eligibility criteria:

        Inclusion Criteria:

          -  A histologically confirmed, locally advanced or metastatic prostate cancer, and naïve
             to androgen deprivation therapy, and a candidate for hormonal treatment.

          -  An estimated survival time of at least twelve months according to the investigator's
             assessment.

          -  A performance status score ≤ 2 according to the World Health Organisation (WHO)
             criteria.

        Exclusion Criteria:

          -  Previous surgical castration.

          -  Previous or has planned curative prostate cancer therapy (radiation/surgery)

          -  Previous hormone therapy (GnRH analogues, estrogens or anti-androgens)

          -  Patients with risk of a serious complication in the case of tumour flare (vertebral
             metastases threatening spinal cord compression or significant obstructive uropathy)
Clinical trial NCT00420589 (phase 3, status: terminated)
Conditions: obesity
ICD codes: E66.8, E66.9, E66.1, O99.214, O99.215, O99.210, O99.211
Drugs: taranabant, comparator: placebo
SMILES: C[C@H](NC(=O)C(C)(C)OC1=CC=C(C=N1)C(F)(F)F)[C@@H](CC1=CC=C(Cl)C=C1)C1=CC=CC(=C1)C#N, CN(C)C(=N)NC(N)=N
Reason stopped: 
    the overall profile does not support development for obesity
  
Eligibility criteria:

        Inclusion Criteria:

          -  Patient has a body mass index (BMI) between 30 kg/m² and 43kg/m² and has maintained a
             stable weight (+/- 3kg) for at least 3 months prior to study start

          -  Patient is male or female >=18 and <= 65 years of age

          -  Patient understands the study procedures and alternative treatments available

          -  Patient is able to read, understand and complete study questionnaires

        Exclusion Criteria:

          -  Patient has a history or presence of a major psychiatric disorder

          -  Patient has a recent history (within 6 months prior to signing the informed consent)
             diagnosis/episode/recurrence of stroke, TIA or neurological disorder

          -  Patient has a history of seizures or is at high risk of developing seizures

          -  Patient has systolic blood pressure >160mm Hg or diastolic blood pressure > 100 mm Hg

          -  Patient has diabetes mellitus as defined by medical history